ArticleJournal of the National Cancer Institute2018

Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.

Kathryn R Tringale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.